Compare Canopy Growth Corp (CGC) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Colgate-Palmolive Company — how do they compare? Canopy Growth Corp trades at $1 (market cap $421.10M), while Colgate-Palmolive Company trades at $92.17 (market cap $73.59B). The key difference: Colgate-Palmolive Company is far larger — about 174.8× Canopy Growth Corp's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | CL | |
|---|---|---|
Market Cap | $421.10M | $73.59B |
Sector | Health | Consumer Staples |
52-Week High | $1.92 | $99.14 |
52-Week Low | $0.86 | $74.98 |
Enterprise Value | $378.55M | $80.07B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CGC trades at $0.95, down 1.86% in the last session, with a neutral technical signal and mixed analyst ratings (9 buy, 11 hold, 7 sell). The company reported Q1 2027 revenue growth of 13% year-over-year, beating estimates, but continues to post net losses. Recent news highlights expansion in European cannabis markets and cost-cutting efforts, while the stock remains volatile amid regulatory uncertainty.
Outlook is cautious due to persistent losses and high debt, though improving cash flow and revenue growth offer potential upside. Key risks include regulatory delays in U.S. cannabis rescheduling and competitive pressures. Investors should weigh the speculative nature against any positive regulatory catalysts.
Colgate-Palmolive (CL) trades at $93.15, down 0.13% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $0.99, beating estimates, with 4.9% sales growth driven by emerging markets. However, North American weakness persists, and valuation ratios like P/E of 36.34 and P/B of 311.81 appear elevated. Cash flow remains positive, and a dividend of $0.53 is scheduled for August 2026.
Outlook is mixed: strong brand presence and dividend sustainability support the stock, but high valuation and domestic challenges pose risks. Analyst consensus price target is $99.10, implying modest upside, with 42% buy ratings. Key risks include competitive pressures and margin compression from inflation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
